Andarix Pharmaceuticals Selected to Present at the 6th JCA-AACR Special Joint Conference on Lung Cancer
The Andarix drug addresses the growing Lung Cancer problem in Asia
SOMERVILLE, Mass.— July 10, 2018 — Andarix Pharmaceuticals, a clinical stage
company, developing a targeted peptide therapy for small cell lung cancer has been
selected to present a poster at the 6th JCA-AACR Special Joint Conference on lung
cancer from July 10-12 in Kyoto, Japan.
The conference is focused on new developments in lung cancer. The conference will
bring together some of the leading lung cancer experts from across the globe to present
and collaborate on therapeutic projects.
Tozaride is a novel, best-in-class therapy for lung and other cancers based on the radio-
labeled somatostatin peptide Tozaride. Early clinical studies of Tozaride demonstrated
that it is well tolerated and may produce prolonged stable disease and improved overall
survival in heavily pre-treated advanced lung cancer patients. Tozaride targeted
radiotherapy represents a new treatment paradigm which is expected to yield significant
clinical benefit for both small cell lung cancer (SCLC), and non-small cell lung cancer
(NSCLC) patients, and which will provide another treatment option for patients who are
not eligible for, or who have not responded to current therapies.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is a clinical stage company developing targeted imaging and
therapies for lung, neuroendocrine, and other cancers based on a proprietary
somatostatin peptide conjugate. Extensive research has demonstrated that somatostatin
receptors are highly up-regulated on several solid tumors, particularly lung cancers.
Lung cancer is the leading cause of cancer mortality in the United States for both men
and women. In 2013, there were an estimated 225,470 new diagnoses of non-small cell
lung cancer (NSCLC) with 42,000 small cell lung cancer patients. To learn more about
Andarix, please visit www.andarix.com .
Andarix Pharmaceuticals Inc